Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

Myocardial tissue characterization using magnetic resonance noncontrast t1 mapping in hypertrophic and dilated cardiomyopathy.

Dass S, Suttie JJ, Piechnik SK, Ferreira VM, Holloway CJ, Banerjee R, Mahmod M, Cochlin L, Karamitsos TD, Robson MD, Watkins H, Neubauer S.

Circ Cardiovasc Imaging. 2012 Nov;5(6):726-33. doi: 10.1161/CIRCIMAGING.112.976738. Epub 2012 Oct 15.

2.

Quantitative diffusion-weighted magnetic resonance imaging in the assessment of myocardial fibrosis in hypertrophic cardiomyopathy compared with T1 mapping.

Wu LM, Chen BH, Yao QY, Ou YR, Wu R, Jiang M, Hu J, An DA, Xu JR.

Int J Cardiovasc Imaging. 2016 Aug;32(8):1289-97. doi: 10.1007/s10554-016-0909-x. Epub 2016 May 19.

PMID:
27198892
3.

Distribution of late gadolinium enhancement in end-stage hypertrophic cardiomyopathy and dilated cardiomyopathy: differential diagnosis and prediction of cardiac outcome.

Machii M, Satoh H, Shiraki K, Saotome M, Urushida T, Katoh H, Takehara Y, Sakahara H, Ohtani H, Wakabayashi Y, Ukigai H, Tawarahara K, Hayashi H.

Magn Reson Imaging. 2014 Feb;32(2):118-24. doi: 10.1016/j.mri.2013.10.011. Epub 2013 Oct 22.

PMID:
24315973
4.

Myocardial fibrosis and quality of life in patients with non-ischemic cardiomyopathy: a cardiovascular magnetic resonance imaging study.

Khan R, Massel D, Stirrat J, Scholl D, Wisenberg G, Thompson T, Drangova M, White JA.

Int J Cardiovasc Imaging. 2013 Feb;29(2):395-404. doi: 10.1007/s10554-012-0107-4. Epub 2012 Aug 9.

PMID:
22875171
5.

Native T1-mapping for non-contrast assessment of myocardial fibrosis in patients with hypertrophic cardiomyopathy--comparison with late enhancement quantification.

Małek ŁA, Werys K, Kłopotowski M, Śpiewak M, Miłosz-Wieczorek B, Mazurkiewicz Ł, Petryka-Mazurkiewicz J, Marczak M, Witkowski A.

Magn Reson Imaging. 2015 Jul;33(6):718-24. doi: 10.1016/j.mri.2015.04.001. Epub 2015 Apr 8.

PMID:
25863138
6.

Extracellular volume fraction mapping in the myocardium, part 2: initial clinical experience.

Kellman P, Wilson JR, Xue H, Bandettini WP, Shanbhag SM, Druey KM, Ugander M, Arai AE.

J Cardiovasc Magn Reson. 2012 Sep 11;14:64. doi: 10.1186/1532-429X-14-64.

7.

Endogenous contrast T1rho cardiac magnetic resonance for myocardial fibrosis in hypertrophic cardiomyopathy patients.

Wang C, Zheng J, Sun J, Wang Y, Xia R, Yin Q, Chen W, Xu Z, Liao J, Zhang B, Gao F.

J Cardiol. 2015 Dec;66(6):520-6. doi: 10.1016/j.jjcc.2015.03.005. Epub 2015 May 14.

8.

Focal myocardial fibrosis assessed by late gadolinium enhancement cardiovascular magnetic resonance in children and adolescents with dilated cardiomyopathy.

Latus H, Gummel K, Klingel K, Moysich A, Khalil M, Mazhari N, Bauer J, Kandolf R, Schranz D, Apitz C.

J Cardiovasc Magn Reson. 2015 May 15;17:34. doi: 10.1186/s12968-015-0142-0.

9.

Novel Cardiac Magnetic Resonance Feature Tracking (CMR-FT) Analysis for Detection of Myocardial Fibrosis in Pediatric Hypertrophic Cardiomyopathy.

Bogarapu S, Puchalski MD, Everitt MD, Williams RV, Weng HY, Menon SC.

Pediatr Cardiol. 2016 Apr;37(4):663-73. doi: 10.1007/s00246-015-1329-8. Epub 2016 Jan 30.

PMID:
26833321
10.

In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy.

Brouwer WP, Baars EN, Germans T, de Boer K, Beek AM, van der Velden J, van Rossum AC, Hofman MB.

J Cardiovasc Magn Reson. 2014 Apr 25;16:28. doi: 10.1186/1532-429X-16-28.

11.

Extracellular volume fraction in dilated cardiomyopathy patients without obvious late gadolinium enhancement: comparison with healthy control subjects.

Hong YJ, Park CH, Kim YJ, Hur J, Lee HJ, Hong SR, Suh YJ, Greiser A, Paek MY, Choi BW, Kim TH.

Int J Cardiovasc Imaging. 2015 Jun;31 Suppl 1:115-22. doi: 10.1007/s10554-015-0595-0. Epub 2015 Jan 30.

PMID:
25634119
12.

T1 Mapping in Discrimination of Hypertrophic Phenotypes: Hypertensive Heart Disease and Hypertrophic Cardiomyopathy: Findings From the International T1 Multicenter Cardiovascular Magnetic Resonance Study.

Hinojar R, Varma N, Child N, Goodman B, Jabbour A, Yu CY, Gebker R, Doltra A, Kelle S, Khan S, Rogers T, Arroyo Ucar E, Cummins C, Carr-White G, Nagel E, Puntmann VO.

Circ Cardiovasc Imaging. 2015 Dec;8(12). pii: e003285. doi: 10.1161/CIRCIMAGING.115.003285.

13.

Investigation of global and regional myocardial mechanics with 3-dimensional speckle tracking echocardiography and relations to hypertrophy and fibrosis in hypertrophic cardiomyopathy.

Urbano-Moral JA, Rowin EJ, Maron MS, Crean A, Pandian NG.

Circ Cardiovasc Imaging. 2014 Jan;7(1):11-9. doi: 10.1161/CIRCIMAGING.113.000842. Epub 2013 Nov 25.

14.

Correlation of electrocardiographic changes and myocardial fibrosis in patients with hypertrophic cardiomyopathy detected by cardiac magnetic resonance imaging.

Song BG, Yang HS, Hwang HK, Kang GH, Park YH, Chun WJ, Oh JH.

Clin Cardiol. 2013 Jan;36(1):31-5. doi: 10.1002/clc.22062. Epub 2012 Oct 15. Retraction in: Clin Cardiol. 2013 Nov;36(11):711.

15.

A comprehensive evaluation of myocardial fibrosis in hypertrophic cardiomyopathy with cardiac magnetic resonance imaging: linking genotype with fibrotic phenotype.

Ellims AH, Iles LM, Ling LH, Chong B, Macciocca I, Slavin GS, Hare JL, Kaye DM, Marasco SF, McLean CA, James PA, du Sart D, Taylor AJ.

Eur Heart J Cardiovasc Imaging. 2014 Oct;15(10):1108-16. doi: 10.1093/ehjci/jeu077. Epub 2014 May 12.

PMID:
24819852
16.

Diffuse myocardial fibrosis in hypertrophic cardiomyopathy can be identified by cardiovascular magnetic resonance, and is associated with left ventricular diastolic dysfunction.

Ellims AH, Iles LM, Ling LH, Hare JL, Kaye DM, Taylor AJ.

J Cardiovasc Magn Reson. 2012 Oct 29;14:76. doi: 10.1186/1532-429X-14-76.

17.

Usefulness of delayed enhancement magnetic resonance imaging to differentiate dilated phase of hypertrophic cardiomyopathy and dilated cardiomyopathy.

Matoh F, Satoh H, Shiraki K, Saitoh T, Urushida T, Katoh H, Takehara Y, Sakahara H, Hayashi H.

J Card Fail. 2007 Jun;13(5):372-9.

PMID:
17602984
18.

Assessment of myocardial deformation with cardiac magnetic resonance strain imaging improves risk stratification in patients with dilated cardiomyopathy.

Buss SJ, Breuninger K, Lehrke S, Voss A, Galuschky C, Lossnitzer D, Andre F, Ehlermann P, Franke J, Taeger T, Frankenstein L, Steen H, Meder B, Giannitsis E, Katus HA, Korosoglou G.

Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):307-15. doi: 10.1093/ehjci/jeu181. Epub 2014 Sep 21.

PMID:
25246506
19.

Letter by Ellims et al regarding article, "myocardial tissue characterization using magnetic resonance noncontrast t1 mapping in hypertrophic and dilated cardiomyopathy".

Ellims AH, Iles LM, Taylor AJ.

Circ Cardiovasc Imaging. 2013 Mar 1;6(2):e1. doi: 10.1161/CIRCIMAGING.112.000064. No abstract available.

20.

T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique.

White SK, Sado DM, Fontana M, Banypersad SM, Maestrini V, Flett AS, Piechnik SK, Robson MD, Hausenloy DJ, Sheikh AM, Hawkins PN, Moon JC.

JACC Cardiovasc Imaging. 2013 Sep;6(9):955-62. doi: 10.1016/j.jcmg.2013.01.011. Epub 2013 Apr 10.

Supplemental Content

Support Center